Genetic study could influence the development of COVID-19 therapies
The study is the first in-depth look at links between COVID-19 severity and gene expression in immune cells and may guide future therapies.
List view / Grid view
The study is the first in-depth look at links between COVID-19 severity and gene expression in immune cells and may guide future therapies.
A new study claims that future COVID-19 vaccines should activate T cells to attack infected cells expressing replication proteins.
Biologics solutions from discovery to manufacturing.
The study used CRISPR to show that DNA “de-methylation” activity can be targeted to anywhere in the DNA and may be a new therapeutic strategy.
The study found that deleting the ABI3 gene in mice increased plaques and inflammation in the brain, suggesting avenues for new treatments.
The peptide-centric chimeric antigen receptors killed neuroblastoma cells in mice and could potentially expand the pool of immunotherapeutic targets.
Treatment with Viking Therapeutics' dual agonists resulted in mean reductions in body weight of up to 27 percent compared to semaglutide-treated animals.
The small molecule successfully targeted the C9orf72 gene that causes amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD).
27 October 2021 | By Takara Bio
Watch this free one-hour session to discover how refined cell atlases can provide comprehensive roadmaps for health and disease.
German, Norwegian and British scientists have identified molecular targets for therapies that could prevent breast cancer recurrence.
This whitepaper overviews phenotypic and functional characterisation of CAR-T cells with advanced flow cytometry and live-cell analysis.
Researchers identified three microRNAs whose levels were associated with mental performance in cells, mice and humans.
Stealth BioTherapeutic's SBT-272 improved mitochondrial motility in a murine model of amyotrophic lateral sclerosis.
Landmark pre-clinical studies to investigate whether psychedelic derivatives can reduce alcohol consumption have been initiated.
Axitinib, a common chemotherapy drug, restored memory and cognitive function in mouse models, representing a potential Alzheimer’s treatment.